Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04225923
Recruitment Status : Recruiting
First Posted : January 13, 2020
Last Update Posted : May 18, 2022
Sponsor:
Information provided by (Responsible Party):
Nobelpharma

Brief Summary:
The primary objective is to assess the efficacy and safety of NPC-21 when administered prophylactically to cytomegalovirus (CMV) seronegative patients receiving a first kidney transplant from a CMV seropositive donor.

Condition or disease Intervention/treatment Phase
Cytomegalovirus Disease Drug: NPC-21 Low dose Drug: NPC-21 High dose Drug: NPC-21 Placebo Phase 2

Detailed Description:
This is a Phase 2, randomized, double-blind, placebo-controlled study of NPC-21 for kidney transplant recipients at high risk of CMV infection in the United States and Japan. Approximately 108 eligible patients will be randomized prior to first study drug administration to receive low-dose NPC 21, high-dose NPC-21, or placebo. Randomization will be stratified by region (United States or Japan)

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 108 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of NPC-21 for Kidney Transplant Recipients at High-Risk of Cytomegalovirus Infection
Actual Study Start Date : June 1, 2020
Estimated Primary Completion Date : November 2022
Estimated Study Completion Date : February 2023


Arm Intervention/treatment
Experimental: NPC-21 Low dose
NPC-21 (Low dose) will be administered
Drug: NPC-21 Low dose
NPC-21 will be administered via an approximately 60-minute intravenous infusion

Experimental: NPC-21 High dose
NPC-21 (High dose) will be administered
Drug: NPC-21 High dose
NPC-21 will be administered via an approximately 60-minute intravenous infusion

Placebo Comparator: NPC-21 Placebo
Placebo (normal saline) will be administered
Drug: NPC-21 Placebo
Placebo will be administered via an approximately 60-minute intravenous infusion




Primary Outcome Measures :
  1. Incidence of CMV disease or CMV viremia [ Time Frame: 16 weeks ]
    Percentage of patients with adjudicated CMV disease or CMV viremia through 16 weeks post-transplant


Secondary Outcome Measures :
  1. Incidence of CMV disease or CMV viremia [ Time Frame: 28 weeks ]
    Percentage of patients with adjudicated CMV disease or CMV viremia.

  2. Incidence of CMV disease [ Time Frame: 28 weeks ]
    Percentage of patients with adjudicated CMV disease

  3. Incidence of CMV viremia [ Time Frame: 28 weeks ]
    Percentage of patients with adjudicated CMV viremia.

  4. Time to detectable CMV disease or CMV viremia [ Time Frame: 28 weeks ]
  5. Time to detectable CMV disease [ Time Frame: 28 weeks ]
  6. Time to detectable CMV viremia [ Time Frame: 28 weeks ]
  7. Amount of CMV DNA [ Time Frame: 28 weeks ]
  8. Incidence and duration of anti-CMV therapy during the Rescue Phase [ Time Frame: 28 weeks ]
  9. Changes in EQ-5D-5L score from Baseline [ Time Frame: 28 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 76 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female patients 18 to 75 years of age in the United States or 20 to 75 years of age in Japan at the time of obtaining informed consent.
  2. Patients must be CMV seronegative pre-transplant and scheduled to receive or have received (within 7 days prior to first study drug administration) a first kidney transplant from a CMV seropositive donor.
  3. Patients must be willing and able to give written informed consent for participation in the study.
  4. Patients must be eligible to undergo kidney transplantation from a living or deceased donor, as per institutional standards.
  5. Patients must agree with contraception by using appropriate contraceptive measures.

Exclusion Criteria:

  1. Patients who have received a previous solid organ transplantation or hematopoietic stem cell transplantation.
  2. Patients who receive a multi-organ transplant.
  3. Patients who have CMV disease or CMV viremia at Screening.
  4. Patients who have a positive donor-specific antibody within 90 days prior to Randomization confirmed via medical records.
  5. Patients whose body weight is more than 120 kg at Screening.
  6. Patients who have received the following anti-CMV therapy within 7 days prior to Randomization and/or plan to receive the following anti-CMV therapy during the study:

    ・ Anti-CMV agents (eg, foscarnet, ganciclovir, valganciclovir, letermovir, high dose acyclovir, high dose valacyclovir, high dose famciclovir, or cidofovir).

    Note: The use of anti-CMV agents per local standard of care during the Rescue Phase of the study is permitted.

    Note: The use of anti-herpes simplex virus and anti-varicella zoster virus prophylaxis for at-risk patients is recommended (as long as the doses are below the one specified above).

  7. Patients who have received the following therapy within 28 days prior to Randomization and/or plan to receive the following anti-CMV therapy during the study:

    • CMV hyperimmune globulin (eg, CytoGam).
    • Intravenous immunoglobulin.
    • Plasmapheresis (receipt prior to first study drug administration is acceptable).
  8. Patients with a history of a serious drug allergy to proteins, immunoglobulins, transfusions, or vaccines or any excipient of the NPC-21 formulation.
  9. Patients with severe hepatic insufficiency at Screening (eg, Child-Pugh Class C).
  10. Patients with active and untreated hepatitis B virus or hepatitis C virus, as documented as part of the pre-transplant screening.
  11. Patients with known human immunodeficiency virus infection, based on medical records serology.
  12. Patients with any uncontrolled infection at Randomization or a history of serious and uncontrolled infection within 6 months prior to Randomization.
  13. Patients who are pregnant or lactating.
  14. Patients with a history of malignancy within 5 years prior to Randomization other than curatively treated in situ cervical carcinoma, cutaneous basal cell carcinoma, or cutaneous squamous cell carcinoma.
  15. Patients with a history of alcohol or drug abuse or dependence within 1 year prior to Randomization that, in the opinion of the Investigator, would preclude study participation.
  16. Patients who have previously participated in this study or any other study involving NPC-21.
  17. Patients who have previously participated or are currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent.
  18. Patients who have participated in another interventional clinical study and received another investigational product (ie, not approved by the Food and Drug Administration in the United States or the Ministry of Health, Labour and Welfare in Japan) within 90 days before Randomization.
  19. Patients who are unable or unwilling, in the opinion of the Investigator, to comply with the protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04225923


Contacts
Layout table for location contacts
Contact: Tatsuya Watanabe +81-3-6670-3812 watanabe.tatsuya@nobelpharma.co.jp
Contact: Nobuyuki Takiguchi :+81-3-6670-3815 takiguchi.nobuyuki@nobelpharma.co.jp

Locations
Show Show 28 study locations
Sponsors and Collaborators
Nobelpharma
Layout table for additonal information
Responsible Party: Nobelpharma
ClinicalTrials.gov Identifier: NCT04225923    
Other Study ID Numbers: NPC-21-2
First Posted: January 13, 2020    Key Record Dates
Last Update Posted: May 18, 2022
Last Verified: May 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cytomegalovirus Infections
Infections
Herpesviridae Infections
DNA Virus Infections
Virus Diseases